# Altitude Lab Portfolio: NephroNovus

**Type:** source
**Status:** Useful
**Confidence:** Low
**Source Type:** Incubator Portfolio Listing
**URL:** https://altitudelab.org/portfolio
**Publisher:** Altitude Lab
**Accessed:** 2026-06-19
**Updated:** 2026-06-19

## Summary

Altitude Lab's public portfolio lists NephroNovus as a therapeutics company estimated founded in 2023, categorized as **Alumni**, with a one-line description of chronic kidney disease drug discovery combining biochemical pathway exploration and computational techniques. A linked resident story by co-founder Kevin Yang (April 2025) adds founder narrative and a stated focus on renal fibrosis but is not a pipeline or funding disclosure.

## Useful Claims

- Portfolio entry name: **NephroNovus**.
- Listed industry: **Therapeutics**.
- Listed estimated founding year: **2023**.
- Listed Altitude Lab status: **Alumni** (not currently listed as Resident).
- Portfolio tagline: "Pioneering the battle against chronic kidney disease by exploring groundbreaking biochemical pathways and utilizing advanced computational techniques."
- Altitude Lab resident story (April 18, 2025, by Kevin Yang) states NephroNovus targets **renal fibrosis** as a driver of chronic kidney disease progression and describes a father–son co-founding team (Kevin Yang on business/strategy; his father as scientific foundation). That article links to `https://www.altitudelab.org/companies/nephronovus` for more detail; the company profile page did not expose additional structured pipeline data when accessed during migration.
- A minimal site at `https://www.nephronovus.com/` exists (branding/placeholder layout only); it does not publish mechanism, program, or team details on pages reviewed.

## Reliability Notes

Portfolio listings validate incubator association and high-level positioning, not clinical data, financing, or reproducible science. Alumni status suggests the company completed or exited Altitude Lab residency — this may differ from older intake notes describing active incubation. No peer-reviewed publications, patents, or regulatory filings tying specific assets to NephroNovus were captured in this source record. Team size, disclosed funding, and lead compounds remain unknown in primary materials reviewed.

## Related Pages

- [NephroNovus](nephronovus.md)

## See Also

- [Building a Startup with My Dad: Lessons in Family, Boundaries, and Trust](https://altitudelab.org/articles/building-a-startup-with-my-dad-lessons-in-family-boundaries-and-trust) — Altitude Lab resident story with renal-fibrosis mission statement (narrative, not technical evidence)